CORE--CLINICAL

核心--临床

• 批准号: 6327570
• 负责人: ALLAN I LEVEY
• 金额: $ 29.05万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-15 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6327570
• 关键词: African American; Alzheimer's disease; Parkinson's disease; apolipoprotein E; biomedical facility; blood chemistry; brain disorder diagnosis; clinical research; cognition disorders; community; computer data analysis; degenerative motor system disease; dementia; extrapyramidal disorder; genotype; human subject; interview; longitudinal human study; mitochondrial DNA; neural degeneration; neuropsychological tests; patient /disease registry; tissue /cell culture; urban area

The Clinical Core will continue to provide a registry of well characterized patients and control subjects to foster clinical and basic scientific research on Alzheimer's disease (AD). To capitalize on the unique strengths and research interests of Emory investigators, the following major cohorts of patients will be recruited and followed: (1) probable AD; (2) Parkinson's disease (PD) without dementia; (3) PD with dementia (PDD); and (4) control subjects without evidence of cognitive or motor impairment. African-American subjects will continue to be recruited through our Satellite Clinic and other sites, maintaining 30% participation in each of our registry cohorts, in parallel with the proportion of African-Americans in our community. Blood will be obtained on patients and control subjects for characterization of mitochondrial DNA, apolipoprotein E genotyping, and other analyses as well as the establishment of lymphoblastoid cell lines by the Molecular Core. Comprehensive and standard neurological and neuropsychological assessment designed to evaluate multiple cognitive and behavioral domains will be performed along with clinical evaluation and quantitative neurophysiological tests of motor function. These data, in combination with molecular and eventual neuropathological information will be a valuable resource for the multidisciplinary group of Emory investigators exploring the heterogeneity of AD, PD, and the overlap among these and other neurodegenerative disorders.

临床核心将继续提供井的注册表 表征患者和对照受试者的临床和基本 阿尔茨海默氏病科学研究（AD）。 利用 埃默里研究人员的独特优势和研究兴趣， 将招募主要的患者队列并遵循：（1） 可能的广告； （2）无痴呆症的帕金森氏病（PD）； （3）PD 痴呆（PDD）; （4）没有认知证据或 运动障碍。 非裔美国人将继续招募 通过我们的卫星诊所和其他站点，维持30％ 与我们的每个注册表队列一起参与 我们社区中非裔美国人的比例。 将获得血液 关于线粒体表征的患者和对照对象 DNA，载脂蛋白E基因分型和其他分析以及 通过分子核建立淋巴母细胞系。 全面和标准的神经和神经心理学评估 旨在评估多个认知和行为领域的旨在 与临床评估和定量一起进行 运动功能的神经生理测试。 这些数据，结合 随着分子和最终的神经病理学信息，将是 多学科研究人员的宝贵资源 探索AD，PD和这些重叠的异质性以及 其他神经退行性疾病。